BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...
Why Summit Therapeutics Stock Was a Winner Today
While it remains to be seen how Summit's oncology turn ultimately shakes out, at this point it is indeed looking like a ...
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...
BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold
Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...
Pharmabiz6d
Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab
This trial is designed to compare the ivonescimab combined regimen, a PD-1/VEGF bispecific antibody internally developed by Akeso, with the durvalumab (PD-L1) combined regimen for the first-line ...
Targeted Oncology2d
Adjuvant/Neoadjuvant Therapies Are Addressed in Lung Cancer
The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.
Benzinga.com6d
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
Ivonescimab achieves hazard ratio of 0.51, beating pembrolizumab in progression-free survival. Summit Therapeutics targets potential $17.9 billion in peak revenue in NSCLC market by 2034.